Volume 19, Issue 2 (March 2017) 19, 244–247; DOI:10.4103/1008-682X.168790
Two-micrometer thulium laser resection of the prostate-tangerine technique in benign prostatic hyperplasia patients with previously negative transrectal prostate biopsy
Jian Zhuo, Hai-Bin Wei, Fei Zhang, Hai-Tao Liu, Fu-Jun Zhao, Bang-Min Han, Xiao-Wen Sun, Jun-Lu , Shu-Jie Xia
1Department of Urology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China; 2Department of Urology, Zhejiang Provincial People’s Hospital,
Xiacheng District, Hangzhou 310014, China.
Correspondence: Dr. J Lu (email@example.com) or Dr. SJ Xia (firstname.lastname@example.org)
Date of Submission 11-Mar-2015 Date of Decision 04-May-2015 Date of Acceptance 10-Sep-2015 Date of Web Publication 05-Jan-2016
The 2‑μm thulium laser resection of the prostate‑tangerine technique (TmLRP‑TT) has been introduced as a minimally invasive
treatment for benign prostatic hyperplasia (BPH). This study was undertaken to assess the clinical efficacy and safety of TmLRP‑TT
for the treatment of BPH patients with previously negative transrectal prostate biopsy. A prospective analysis of 51 patients with
previously negative transrectal prostate biopsy who underwent surgical treatment using TmLRP‑TT was performed from December
2011 to December 2013. Preoperative status, surgical details, and perioperative complications were recorded. The follow‑up
outcome was evaluated with subjective and objective tests at 1 and 6 months. TmLRP‑TT was successfully completed in all patients.
Mean prostate volume, operative duration, and catheterization time were 93.3 ± 37.9 ml, 69.5 ± 39.5 min, and 6.5 ± 1.3 days,
respectively. The mean International Prostate Symptom Score, quality of life score, maximum urinary flow rate, and post‑void
residual urine volume changed notably at 6‑month follow‑up (22.5 ± 6.9 vs 6.1 ± 3.2, 4.8 ± 1.3 vs 1.1 ± 0.9, 7.3 ± 4.5 vs
18.9 ± 7.1 ml s−1, and 148.7 ± 168.7 vs 28.4 ± 17.9 ml). Two (3.9%) patients required blood transfusion perioperatively, while
3 (5.9%) patients experienced transient hematuria postoperatively, and 2 (3.9%) patients received 3 days recatheterization due
to clot retention. TmLRP‑TT is a safe and effective minimally invasive technique for patients with previously negative transrectal
prostate biopsy during the 6‑month follow‑up. This promising technology may be a feasible surgical method for previously negative
transrectal prostate biopsy in the future.
Full Text |